My five bucker valuation was for Christmas 2018 and on the assumption of FDA approval. The shorter route as you mention above may be an added bonus but I am certainly not getting too aroused. This one is a real 366day CGT saver for me. It is a daggy as all hell company but I am getting a dividend and it is profitable. This could do some serious running mid year but it is nature of the biotech sector as was previously adequately described.
What I also like is that they are self funding this USA clinical trial. Another feather in their cap folks. This means ALL the spoils will go to them.
Surely in the future they will tag along with some big American company to get this really going. And I am also hoping for some sort of 'lateral application bonus' with CYC where some bright spark thinks up of some extra revenue stream.
In the meantime, it just sits ....waiting........and just goes about its business.
The beauty is the MC of $65M.
CYC Price at posting:
95.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)